FAQ
What is CAR T-Cell Therapy?
CAR T-Cell Therapy (Chimeric Antigen Receptor T-Cell Therapy) is an advanced form of immunotherapy that modifies a patient’s own T cells to recognize and destroy cancer cells. It is primarily used to treat certain blood cancers.
How Does CAR T-Cell Therapy Work?
-
Collection: T cells are collected from the patient’s blood.
-
Modification: These cells are genetically engineered in a lab to express CARs that target cancer cells.
-
Expansion: The modified cells are multiplied in large numbers.
-
Infusion: After chemotherapy, the CAR T-cells are infused back into the patient.
-
Action: The CAR T-cells seek out and destroy cancer cells.
What Cancers Can Be Treated with CAR T-Cell Therapy?
CAR T-Cell Therapy is approved for several blood cancers, including:
-
B-cell acute lymphoblastic leukemia (ALL)
-
Multiple myeloma (MM)
-
​Non-Hodgkin lymphoma (NHL)
What Are the Side Effects of CAR T-Cell Therapy?
Side effects may include:
-
Cytokine Release Syndrome (CRS): fever, low blood pressure, breathing difficulties
-
Neurotoxicity (ICANS): confusion, seizures, difficulty speaking
-
Infections: due to reduced immune cells
-
Fatigue, allergic reactions, and electrolyte imbalances
What is the Future of CAR T-Cell Therapy?
CAR T-Cell Therapy is evolving rapidly. Researchers are exploring its use in solid tumors, developing multi-targeted CARs, and improving customization for specific patient needs. It is considered a “living drug” due to its ability to persist and continue fighting cancer.